Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cust Anne E, Kaaks Rudolf, Friedenreich Christine, Bonnet Fabrice, Laville Martine, Lukanova Annekatrin, Rinaldi Sabina, Dossus Laure, Slimani Nadia, Lundin Eva, Tjønneland Anne, Olsen Anja, Overvad Kim, Clavel-Chapelon Françoise, Mesrine Sylvie, Joulin Virginie, Linseisen Jakob, Rohrmann Sabine, Pischon Tobias, Boeing Heiner, Trichopoulos Dimitrios, Trichopoulou Antonia, Benetou Vassiliki, Palli Domenico, Berrino Franco, Tumino Rosario, Sacerdote Carlotta, Mattiello Amalia, Quirós J Ramón, Mendez Michelle A, Sánchez María-José, Larrañaga Nerea, Tormo M J, Ardanaz Eva, Bueno-de-Mesquita H Bas, Peeters Petra H M, van Gils Carla H, Khaw Kay-Tee, Bingham Sheila, Allen Naomi, Key Tim, Jenab Mazda, Riboli Elio
Аннотация
METHODS: We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition to examine the relation between prediagnostic plasma adiponectin levels and endometrial cancer risk. Among pre- and postmenopausal women who were not currently using exogenous hormones, 284 women developed incident endometrial cancer during an average of 5.1 yr of follow-up. Using risk set sampling, 548 control subjects were selected, matched on center, age, menopausal status, phase of menstrual cycle, time of blood draw, and fasting status. Conditional logistic regression models were used to estimate relative risks and 95% confidence intervals.
RESULTS: Adiponectin levels were inversely associated with endometrial cancer risk [body mass index-adjusted relative risk for the top vs. bottom quartile = 0.56 (95% confidence interval 0.36-0.86), P(trend) = 0.006]. There was evidence of a stronger inverse association among obese women than among nonobese women (P(heterogeneity) = 0.03). The inverse association also appeared stronger for women who were postmenopausal or perimenopausal than premenopausal at baseline, but this was not statistically significantly heterogeneous (P(heterogeneity) = 0.51). The association remained statistically significant after separate adjustment for other obesity-related physiological risk factors such as C-peptide, IGF binding protein-1, IGF binding protein-2, SHBG, estrone, or free testosterone but only marginally statistically significant after simultaneous adjustment for these factors.
CONCLUSIONS: High circulating adiponectin levels are associated with reduced endometrial cancer risk, largely independent of other obesity-related risk factors.